oasis 4 semaglutide 25 mg Oral Wegovy approved for obesity management by FDA on December 23, 2025 Formulation: High‑dose oral (25 daily) — previously only available as weekly injections. Indication: Adults with obesity (BMI ≥30) 🚨 Oral Semaglutide 25 mg

The FDA has claimed that as of April 30, it has received 1,000 reports of adverse side effects caused by compounded GLP-1 medications

7 , 225235 [doi] (2006)

These everyday experiences have a real impact on your cortisol rhythm, and at Blossom, we take the time to explore all of that with you

FDA-approved branded GLP-1s with manufacturer assistance programs

Mediated by the pulmonary mucosa, these treatments can often be optimized, and even enabled, by managing and improving mucosal barrier function 10

Additionally, GLP-1 RA use was associated with a lower cumulative incidence of obesity-related cancers across all subgroups except for Black race